|
Serious adverse events
|
Ezetimibe/Simvastatin |
Simvastatin |
|
Total subjects affected by serious adverse events
|
|
|
|
subjects affected / exposed
|
3640 / 9067 (40.15%) |
3649 / 9077 (40.20%) |
|
number of deaths (all causes)
|
347 |
325 |
|
number of deaths resulting from adverse events
|
10 |
16 |
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
Acute Monocytic Leukaemia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acute Leukaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
Abdominal Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acoustic Neuroma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
1 / 10 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
Adenocarcinoma Gastric
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
2 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
1 / 3 |
|
Adenocarcinoma Of Colon
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
2 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Adenocarcinoma Pancreas
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
Adenoma Benign
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 5 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adenolymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acute Myeloid Leukaemia
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
Adrenal Adenoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adrenal Gland Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adrenal Neoplasm
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Angiomyolipoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Angiosarcoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Anal Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Basosquamous Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Basal Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
140 / 9067 (1.54%) |
157 / 9077 (1.73%) |
|
occurrences causally related to treatment / all
|
2 / 140 |
3 / 157 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
B-Cell Small Lymphocytic Lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atypical Fibroxanthoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
B-Cell Lymphoma Stage I
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Anorectal Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Bone Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
B-Cell Lymphoma
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Benign Neoplasm Of Bladder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Lung Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Duodenal Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Breast Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Ear Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Neoplasm Of Prostate
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Neoplasm Of Skin
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Neoplasm Of Thyroid Gland
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Pancreatic Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Salivary Gland Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Benign Neoplasm Of Conjunctiva
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Neoplasm
|
|
|
|
subjects affected / exposed
|
17 / 9067 (0.19%) |
23 / 9077 (0.25%) |
|
occurrences causally related to treatment / all
|
0 / 17 |
0 / 23 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Bladder Cancer Stage 0, With Cancer In Situ
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Cancer
|
|
|
|
subjects affected / exposed
|
32 / 9067 (0.35%) |
41 / 9077 (0.45%) |
|
occurrences causally related to treatment / all
|
2 / 32 |
2 / 41 |
|
deaths causally related to treatment / all
|
1 / 4 |
0 / 1 |
|
Biliary Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Bile Duct Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
Benign Small Intestinal Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Transitional Cell Carcinoma Stage Ii
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Transitional Cell Carcinoma Recurrent
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Transitional Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
1 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Papilloma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Bone Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Bladder Transitional Cell Carcinoma Stage Iii
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Breast Cancer
|
|
|
|
subjects affected / exposed
|
32 / 9067 (0.35%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
1 / 32 |
1 / 22 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Brain Neoplasm
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Brain Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bowen's Disease
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Sarcoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Bone Neoplasm
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Giant Cell Tumour
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Burkitt's Lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Bronchioloalveolar Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchial Carcinoma
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
Breast Neoplasm
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Breast Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Breast Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Breast Cancer In Situ
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carcinoid Tumour
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carcinoid Tumour Pulmonary
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carcinoma In Situ
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervix Carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Central Nervous System Lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Valve Fibroelastoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cancer Pain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholangiocarcinoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
1 / 4 |
|
deaths causally related to treatment / all
|
1 / 2 |
0 / 3 |
|
Cholesteatoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chondroma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chondrosarcoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervix Carcinoma Stage 0
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Lymphocytic Leukaemia Stage 1
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Lymphocytic Leukaemia
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
1 / 6 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Chronic Myeloid Leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colon Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
Colon Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colon Cancer
|
|
|
|
subjects affected / exposed
|
32 / 9067 (0.35%) |
28 / 9077 (0.31%) |
|
occurrences causally related to treatment / all
|
3 / 32 |
2 / 28 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
Chronic Myelomonocytic Leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Clear Cell Renal Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colon Adenoma
|
|
|
|
subjects affected / exposed
|
23 / 9067 (0.25%) |
29 / 9077 (0.32%) |
|
occurrences causally related to treatment / all
|
0 / 23 |
0 / 29 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Cranial Nerve Neoplasm Benign
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colorectal Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Colorectal Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colorectal Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Colon Cancer Stage Iv
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colon Cancer Stage Iii
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colon Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dysplastic Naevus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ear Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endocrine Neoplasm Malignant
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endometrial Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Enteropathy-Associated T-Cell Lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Essential Thrombocythaemia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diffuse Large B-Cell Lymphoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Gallbladder Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibrosarcoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extradural Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibroma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extramammary Paget's Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eye Naevus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fallopian Tube Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Gastrointestinal Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Carcinoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Gastric Cancer
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
1 / 8 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
Gallbladder Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Cancer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Gastric Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Tract Adenoma
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
20 / 9077 (0.22%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
1 / 20 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrooesophageal Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Glioblastoma
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Glioblastoma Multiforme
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Glioma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemangioma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Stromal Tumour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Adenoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Cancer
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
2 / 9 |
1 / 7 |
|
deaths causally related to treatment / all
|
2 / 5 |
1 / 3 |
|
Hepatic Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Hairy Cell Leukaemia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemangioma Of Bone
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemangioma Of Liver
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemangioma Of Spleen
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypergammaglobulinaemia Benign Monoclonal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Huerthle Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hodgkin's Disease
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Hepatocellular Carcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Hypopharyngeal Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Immunoblastic Lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatobiliary Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intraductal Papillary-Mucinous Carcinoma Of Pancreas
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intraductal Papillary Mucinous Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Insulinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inflammatory Pseudotumour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inflammatory Carcinoma Of The Breast
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Intraocular Melanoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Invasive Ductal Breast Carcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Invasive Lobular Breast Carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Cell Lung Cancer Stage Iii
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Cell Lung Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Keratoacanthoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intraductal Proliferative Breast Lesion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Leiomyosarcoma Metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leiomyoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leiomyosarcoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Laryngeal Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Cancer
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
Large Intestine Benign Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leiomyosarcoma Recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lip Neoplasm Malignant Stage Unspecified
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lip And/Or Oral Cavity Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leukaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
1 / 4 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 3 |
|
Lip Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lipoma
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Liposarcoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Lentigo Maligna
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Carcinoma Cell Type Unspecified Stage 0
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Lung Carcinoma Cell Type Unspecified Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Lung Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 7 |
0 / 11 |
|
Lung Adenocarcinoma Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Adenocarcinoma Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Lung Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
1 / 11 |
0 / 16 |
|
deaths causally related to treatment / all
|
1 / 5 |
0 / 5 |
|
Lobular Breast Carcinoma In Situ
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphoproliferative Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphoma
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
Lymphocytic Leukaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Neoplasm Malignant
|
|
|
|
subjects affected / exposed
|
65 / 9067 (0.72%) |
66 / 9077 (0.73%) |
|
occurrences causally related to treatment / all
|
4 / 65 |
0 / 66 |
|
deaths causally related to treatment / all
|
0 / 30 |
0 / 41 |
|
Lung Neoplasm
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
Lung Carcinoma Cell Type Unspecified Stage Iv
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 2 |
|
Lung Carcinoma Cell Type Unspecified Stage I
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Malignant Melanoma
|
|
|
|
subjects affected / exposed
|
28 / 9067 (0.31%) |
26 / 9077 (0.29%) |
|
occurrences causally related to treatment / all
|
1 / 28 |
0 / 26 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Melanoma In Situ
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
1 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Melanoma Stage I
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Neoplasm Of Ampulla Of Vater
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Neoplasm Of Eyelid
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Neoplasm Of Pleura
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Ascites
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Mantle Cell Lymphoma Stage Iii
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Medullary Thyroid Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Melanocytic Naevus
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mantle Cell Lymphoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Neoplasm Of Unknown Primary Site
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Malignant Neoplasm Progression
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Malignant Urinary Tract Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Meningioma Benign
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mesenteric Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mesothelioma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Mesothelioma Malignant
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Metastases To Adrenals
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastases To Bone
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
Meningioma
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastases To Pelvis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Metastases To Pancreas
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastases To Lymph Nodes
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastases To Lung
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
1 / 6 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 4 |
|
Metastases To Liver
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
2 / 9 |
|
deaths causally related to treatment / all
|
0 / 5 |
2 / 4 |
|
Metastases To Gastrointestinal Tract
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Metastases To Central Nervous System
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
1 / 10 |
1 / 6 |
|
deaths causally related to treatment / all
|
0 / 4 |
1 / 2 |
|
Metastatic Gastric Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Metastatic Choriocarcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastatic Carcinoma Of The Bladder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Metastatic Carcinoid Tumour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Metastasis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 5 |
|
Metastases To The Mediastinum
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastases To Peritoneum
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastatic Malignant Melanoma
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
Metastatic Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
Metastatic Renal Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Mucoepidermoid Carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Monoclonal Gammopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metastatic Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Metastatic Lymphoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Mycosis Fungoides Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myelodysplastic Syndrome
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
1 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Myelofibrosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myeloid Leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Myeloproliferative Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Sinus Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Mycosis Fungoides
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Natural Killer-Cell Leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neoplasm Malignant
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
Neoplasm Prostate
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
1 / 4 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Neoplasm Skin
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuroendocrine Carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Nasopharyngeal Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Non-Hodgkin's Lymphoma Recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Non-Hodgkin's Lymphoma
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Neuroma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neurofibroma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuroendocrine Tumour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuroendocrine Carcinoma Metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Non-Secretory Adenoma Of Pituitary
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Carcinoma Recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Carcinoma
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
1 / 10 |
0 / 8 |
|
deaths causally related to treatment / all
|
1 / 5 |
0 / 3 |
|
Oesophageal Adenocarcinoma Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Non-Small Cell Lung Cancer
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
2 / 8 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
Ocular Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Non-Small Cell Lung Cancer Stage Iiia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Non-Small Cell Lung Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Oesophageal Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ovarian Adenoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteochondroma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Oral Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oligodendroglioma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oral Neoplasm Benign
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Carcinoma Stage Iv
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Pancreatic Carcinoma Metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
2 / 6 |
|
deaths causally related to treatment / all
|
0 / 2 |
2 / 5 |
|
Pancreatic Carcinoma
|
|
|
|
subjects affected / exposed
|
17 / 9067 (0.19%) |
20 / 9077 (0.22%) |
|
occurrences causally related to treatment / all
|
0 / 17 |
2 / 20 |
|
deaths causally related to treatment / all
|
0 / 14 |
1 / 15 |
|
Ovarian Cancer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Ovarian Epithelial Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ovarian Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ovarian Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Pharyngeal Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Phaeochromocytoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pelvic Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Neoplasm
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
2 / 6 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 2 |
|
Paraproteinaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Papilloma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Papillary Thyroid Cancer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Parathyroid Tumour Benign
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pleural Mesothelioma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Pleomorphic Liposarcoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pleomorphic Adenoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pituitary Tumour Benign
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Plasma Cell Myeloma
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
1 / 6 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
Pituitary Tumour Recurrent
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Plasmacytoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostate Cancer Stage Ii
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostate Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostate Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
1 / 12 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
Pleural Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prolactin-Producing Pituitary Tumour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polycythaemia Vera
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostate Cancer
|
|
|
|
subjects affected / exposed
|
123 / 9067 (1.36%) |
117 / 9077 (1.29%) |
|
occurrences causally related to treatment / all
|
7 / 123 |
3 / 117 |
|
deaths causally related to treatment / all
|
0 / 11 |
0 / 6 |
|
Rectal Neoplasm
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
1 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
Rectal Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Prostatic Adenoma
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Adenoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Adenocarcinoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
2 / 6 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
Rectal Cancer
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
1 / 14 |
0 / 11 |
|
deaths causally related to treatment / all
|
1 / 4 |
0 / 2 |
|
Renal Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
19 / 9077 (0.21%) |
|
occurrences causally related to treatment / all
|
1 / 5 |
1 / 19 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Renal Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectosigmoid Cancer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Cancer
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
1 / 7 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Renal Adenoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Schwannoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sarcomatoid Mesothelioma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Sarcoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Oncocytoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Salivary Gland Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Salivary Gland Adenoma
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Salivary Gland Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Small Cell Lung Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
Small Cell Lung Cancer
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
1 / 12 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 9 |
0 / 5 |
|
Small Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
Seborrhoeic Keratosis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Cancer
|
|
|
|
subjects affected / exposed
|
18 / 9067 (0.20%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 18 |
1 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Seminoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Papilloma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma Of The Oral Cavity
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma Of Skin
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 13 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma Of Lung
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 6 |
0 / 1 |
|
Small Intestine Carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
84 / 9067 (0.93%) |
91 / 9077 (1.00%) |
|
occurrences causally related to treatment / all
|
1 / 84 |
4 / 91 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Spindle Cell Sarcoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma Of Head And Neck
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thymoma Malignant
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Throat Cancer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Squamous Cell Carcinoma Of The Tongue
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
T-Cell Lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
Sweat Gland Tumour
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Testis Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tongue Neoplasm Malignant Stage Unspecified
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tongue Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Neoplasm
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thymoma Malignant Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Cancer
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
1 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Adenoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Cancer Metastatic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Transitional Cell Carcinoma
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
1 / 15 |
3 / 8 |
|
deaths causally related to treatment / all
|
0 / 3 |
1 / 1 |
|
Tracheal Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ureteric Cancer Recurrent
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ureteric Cancer
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheal Cancer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Ureteral Neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urethral Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tumour Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterine Leiomyoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterine Cancer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Tract Neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Bladder Sarcoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Bladder Adenoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular disorders
|
|
|
|
Aneurysm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Accelerated Hypertension
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Dilatation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Aneurysm Rupture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Angiopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Aneurysm
|
|
|
|
subjects affected / exposed
|
29 / 9067 (0.32%) |
40 / 9077 (0.44%) |
|
occurrences causally related to treatment / all
|
0 / 29 |
0 / 40 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
Angiodysplasia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arterial Occlusive Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arterial Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Stenosis
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Rupture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Dissection
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Behcet's Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Pressure Fluctuation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Pressure Inadequately Controlled
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arterial Thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arteriosclerosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Embolism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Essential Hypertension
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extremity Necrosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arteriovenous Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Deep Vein Thrombosis
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
33 / 9077 (0.36%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 33 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertensive Emergency
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertensive Crisis
|
|
|
|
subjects affected / exposed
|
21 / 9067 (0.23%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 21 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertension
|
|
|
|
subjects affected / exposed
|
25 / 9067 (0.28%) |
27 / 9077 (0.30%) |
|
occurrences causally related to treatment / all
|
0 / 25 |
0 / 27 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhage
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haematoma
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 16 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Granulomatosis With Polyangiitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Femoral Artery Occlusion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypotension
|
|
|
|
subjects affected / exposed
|
27 / 9067 (0.30%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 27 |
0 / 16 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Hot Flush
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Femoral Artery Aneurysm
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphatic Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leriche Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Jugular Vein Thrombosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ischaemia
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Lymphoedema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intermittent Claudication
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Iliac Artery Occlusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypovolaemic Shock
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
Lymphocele
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intra-Abdominal Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Necrosis Ischaemic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neurogenic Shock
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Orthostatic Hypotension
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Artery Aneurysm
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Arterial Occlusive Disease
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Artery Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Artery Thrombosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Embolism
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Ischaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Vascular Disorder
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malignant Hypertension
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Thrombotic Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Phlebitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subclavian Artery Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Superior Vena Cava Occlusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Superior Vena Cava Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thrombophlebitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Temporal Arteritis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thrombophlebitis Superficial
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Shock Haemorrhagic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Varicose Vein
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular Occlusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vasculitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vasculitis Necrotising
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Venous Insufficiency
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Venous Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Venous Thrombosis Limb
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Varicose Ulceration
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Surgical and medical procedures
|
|
|
|
Appendicectomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthrodesis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Finger Amputation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fascia Release
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colostomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cataract Operation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Rehabilitation Therapy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholecystectomy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Catheterisation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Pacemaker Replacement
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrectomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colectomy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Implantable Defibrillator Insertion
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Immunoglobulin Therapy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ileostomy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hip Surgery
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hip Arthroplasty
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hernia Repair
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Surgery
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Bypass
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hospitalisation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intraocular Lens Implant
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Arthroplasty
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mammoplasty
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Knee Operation
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 13 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incisional Hernia Repair
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Knee Arthroplasty
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Septal Operation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Polypectomy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mitral Valve Repair
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Penile Prosthesis Insertion
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Preoperative Care
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prophylaxis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatectomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rehabilitation Therapy
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Percutaneous Coronary Intervention
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Shoulder Arthroplasty
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Shoulder Operation
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Decompression
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Surgery
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rotator Cuff Repair
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroidectomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Suture Removal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tooth Extraction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Transurethral Bladder Resection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Transurethral Prostatectomy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Turbinectomy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Varicose Vein Operation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertebroplasty
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
General disorders and administration site conditions
|
|
|
|
Adverse Drug Reaction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Brca2 Gene Mutation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adverse Event
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adverse Reaction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Asthenia
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
1 / 14 |
0 / 18 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Catheter Site Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chest Discomfort
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Battery Issue
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cyst Rupture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chills
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cyst
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Complication Of Device Insertion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Breakage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chest Pain
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Failure
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Issue
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Lead Damage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Lead Issue
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Malfunction
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Dislocation
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Discomfort
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Occlusion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Feeling Cold
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fatigue
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fat Necrosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Drug Withdrawal Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gait Disturbance
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibrosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Generalised Oedema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Granuloma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Feeling Hot
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
General Physical Health Deterioration
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Implant Site Extravasation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Impaired Healing
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypothermia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperplasia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hernia Obstructive
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hernia
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malaise
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
1 / 8 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Local Swelling
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Influenza Like Illness
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inflammation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Implant Site Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Injection Site Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metaplasia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Necrosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Multi-Organ Failure
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Mucosal Inflammation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Medical Device Complication
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pacemaker Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pain
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pelvic Mass
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Pacemaker Generated Arrhythmia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Non-Cardiac Chest Pain
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
0 / 16 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oedema Peripheral
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polyp
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pyrexia
|
|
|
|
subjects affected / exposed
|
24 / 9067 (0.26%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 24 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Stent-Graft Endoleak
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Submandibular Mass
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Systemic Inflammatory Response Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Puncture Site Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ulcer
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ulcer Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Xerosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thrombosis In Device
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Immune system disorders
|
|
|
|
Allergy To Arthropod Sting
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaphylactic Reaction
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaphylactic Shock
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Autoimmune Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Drug Hypersensitivity
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypersensitivity
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
3 / 8 |
1 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Seasonal Allergy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Social circumstances
|
|
|
|
Cardiac Assistance Device User
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Reproductive system and breast disorders
|
|
|
|
Benign Prostatic Hyperplasia
|
|
|
|
subjects affected / exposed
|
72 / 9067 (0.79%) |
72 / 9077 (0.79%) |
|
occurrences causally related to treatment / all
|
0 / 72 |
0 / 72 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Breast Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Erectile Dysfunction
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endometrial Hypertrophy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endometrial Hyperplasia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Breast Mass
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Polyp
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Dysplasia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cystocele
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pelvic Haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ovarian Mass
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ovarian Cyst
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Female Genital Tract Fistula
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gynaecomastia
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibrocystic Breast Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Menorrhagia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pelvic Prolapse
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Penis Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Penile Vein Thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peyronie's Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postmenopausal Haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatic Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatic Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatism
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatic Dysplasia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatic Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatitis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatomegaly
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectoprostatic Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Scrotal Haematocoele
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vaginal Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterine Prolapse
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterine Polyp
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vaginal Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterovaginal Prolapse
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spermatocele
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Uterine Inflammation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vaginal Prolapse
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vaginal Hyperplasia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Acute Pulmonary Oedema
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Acute Respiratory Distress Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Acute Respiratory Failure
|
|
|
|
subjects affected / exposed
|
18 / 9067 (0.20%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 18 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
Asphyxia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Asthma
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
0 / 13 |
0 / 17 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Atelectasis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchial Hyperreactivity
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchial Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchiectasis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchopneumopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchopulmonary Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchial Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Obstructive Pulmonary Disease
|
|
|
|
subjects affected / exposed
|
109 / 9067 (1.20%) |
105 / 9077 (1.16%) |
|
occurrences causally related to treatment / all
|
1 / 109 |
0 / 105 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
Bronchospasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Respiratory Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cough
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dyspnoea
|
|
|
|
subjects affected / exposed
|
47 / 9067 (0.52%) |
56 / 9077 (0.62%) |
|
occurrences causally related to treatment / all
|
1 / 47 |
0 / 56 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
Dyspnoea Exertional
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dyspnoea Paroxysmal Nocturnal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Emphysema
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epistaxis
|
|
|
|
subjects affected / exposed
|
23 / 9067 (0.25%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 23 |
1 / 16 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemoptysis
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Haemothorax
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperventilation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypoxia
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Idiopathic Pulmonary Fibrosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Interstitial Lung Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Oedema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Polyp
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Ulceration
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngeal Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngospasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Disorder
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Hernia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Infiltration
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Polyps
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Turbinate Hypertrophy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Septum Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasal Septum Deviation
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oropharyngeal Pain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Organising Pneumonia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Obstructive Airways Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Orthopnoea
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pickwickian Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pleural Effusion
|
|
|
|
subjects affected / exposed
|
24 / 9067 (0.26%) |
24 / 9077 (0.26%) |
|
occurrences causally related to treatment / all
|
0 / 24 |
0 / 24 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Pleural Fibrosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pleurisy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumothorax Spontaneous
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Aspiration
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
Pulmonary Arterial Hypertension
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pleuritic Pain
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumothorax
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonitis
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Embolism
|
|
|
|
subjects affected / exposed
|
46 / 9067 (0.51%) |
36 / 9077 (0.40%) |
|
occurrences causally related to treatment / all
|
0 / 46 |
0 / 36 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
Pulmonary Fibrosis
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Pulmonary Hypertension
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Granuloma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Respiratory Arrest
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
Respiratory Acidosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Respiratory Distress
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Respiratory Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Oedema
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Pulmonary Mass
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
1 / 22 |
|
deaths causally related to treatment / all
|
0 / 2 |
1 / 1 |
|
Respiratory Failure
|
|
|
|
subjects affected / exposed
|
32 / 9067 (0.35%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 32 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 9 |
0 / 7 |
|
Restrictive Pulmonary Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sleep Apnoea Syndrome
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheal Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Status Asthmaticus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheomalacia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vocal Cord Leukoplakia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vocal Cord Inflammation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vocal Cord Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Upper Respiratory Tract Inflammation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vocal Cord Polyp
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Psychiatric disorders
|
|
|
|
Acute Psychosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abnormal Behaviour
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bipolar I Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bipolar Disorder
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anxiety Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alcohol Withdrawal Syndrome
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alcoholism
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anxiety
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alcohol Abuse
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Delirium Tremens
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Delirium
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Conversion Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Confusional State
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Completed Suicide
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Burnout Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bipolar Ii Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypomania
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Insomnia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Major Depression
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hallucination
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Depression
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 17 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Disorientation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Generalised Anxiety Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post-Traumatic Stress Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Paranoia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Panic Attack
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neurosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mental Status Changes
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Mental Disorder Due To A General Medical Condition
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mental Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Somatisation Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Somatoform Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Stress
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sleep Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Schizophrenia, Paranoid Type
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Schizophrenia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Psychotic Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Withdrawal Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Suicide Attempt
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Suicidal Ideation
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatobiliary disorders
|
|
|
|
Alcoholic Liver Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bile Duct Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bile Duct Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholangitis Acute
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholangitis
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
2 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Biliary Tract Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Biliary Dyskinesia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Biliary Colic
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bile Duct Stone
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
1 / 7 |
2 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cirrhosis Alcoholic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholestasis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
2 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
Cholelithiasis
|
|
|
|
subjects affected / exposed
|
78 / 9067 (0.86%) |
71 / 9077 (0.78%) |
|
occurrences causally related to treatment / all
|
3 / 78 |
6 / 71 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholecystitis Chronic
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
1 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholecystitis Acute
|
|
|
|
subjects affected / exposed
|
27 / 9067 (0.30%) |
26 / 9077 (0.29%) |
|
occurrences causally related to treatment / all
|
0 / 27 |
0 / 26 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholecystitis
|
|
|
|
subjects affected / exposed
|
47 / 9067 (0.52%) |
73 / 9077 (0.80%) |
|
occurrences causally related to treatment / all
|
3 / 47 |
10 / 73 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Gallbladder Cholesterolosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Disorder
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
1 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Pain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Polyp
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Drug-Induced Liver Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Granulomatous Liver Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Steatosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Cirrhosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Hepatic Cyst
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Failure
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Hepatic Mass
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatorenal Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Hydrocholecystis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperbilirubinaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ischaemic Hepatitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Jaundice
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Jaundice Cholestatic
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Liver Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Portal Hypertension
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Portal Vein Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Investigations
|
|
|
|
Blood Creatinine Increased
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Creatine Phosphokinase Increased
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
3 / 4 |
2 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anticoagulation Drug Level Below Therapeutic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Creatine Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alanine Aminotransferase Increased
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Glucose Abnormal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Lactate Dehydrogenase Increased
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Glucose Increased
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Pressure Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood Urine Present
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Body Temperature Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Blood Pressure Orthostatic Decreased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Electrocardiogram Repolarisation Abnormality
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Electrocardiogram Qt Prolonged
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ejection Fraction Decreased
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Clostridium Test Positive
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endoscopy Gastrointestinal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endoscopy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colonoscopy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Examination
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemoglobin Decreased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heart Rate Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heart Rate Irregular
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Enzyme Increased
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
3 / 3 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
International Normalised Ratio Decreased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heart Rate Decreased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laboratory Test Abnormal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Liver Function Test Abnormal
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
3 / 4 |
3 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Occult Blood Positive
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Precancerous Cells Present
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
International Normalised Ratio Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Psychiatric Evaluation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostatic Specific Antigen Increased
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tumour Marker Increased
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Transaminases Increased
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
2 / 2 |
3 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Total Lung Capacity Decreased
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Weight Increased
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Weight Decreased
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Injury, poisoning and procedural complications
|
|
|
|
Abdominal Wound Dehiscence
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Accidental Overdose
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acetabulum Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alcohol Poisoning
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia Postoperative
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anastomotic Leak
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anastomotic Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ankle Fracture
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arterial Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Animal Bite
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Contusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Vertebral Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthropod Sting
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carbon Monoxide Poisoning
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bursa Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Burns Second Degree
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Contusion
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Concussion
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Clavicle Fracture
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chest Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chemical Poisoning
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chance Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Compression Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Craniocerebral Injury
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Electric Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epicondylitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eye Penetration
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Face Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Coronary Artery Restenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibula Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Femur Fracture
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Femoral Neck Fracture
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fat Embolism
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fall
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Facial Bones Fracture
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Foreign Body
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fracture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fractured Sacrum
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fractured Ischium
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Foot Fracture
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Forearm Fracture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heat Illness
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heat Exhaustion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Head Injury
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Hand Fracture
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gun Shot Wound
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis Radiation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Anastomotic Leak
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incisional Hernia, Obstructive
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incisional Hernia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incision Site Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Humerus Fracture
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hip Fracture
|
|
|
|
subjects affected / exposed
|
28 / 9067 (0.31%) |
23 / 9077 (0.25%) |
|
occurrences causally related to treatment / all
|
0 / 28 |
1 / 23 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Heat Stroke
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Injury
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intentional Overdose
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Jaw Fracture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Dislocation
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Injury
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Kidney Contusion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inflammation Of Wound
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Kidney Rupture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laceration
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ligament Rupture
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Limb Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Limb Traumatic Amputation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Limb Fracture
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Limb Crushing Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscle Rupture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Meniscus Injury
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mouth Injury
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Multiple Fractures
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Multiple Injuries
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Lumbar Vertebral Fracture
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pelvic Fracture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Patella Fracture
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Overdose
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
1 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Leak
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Open Fracture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscle Strain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Near Drowning
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Concussion Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Poisoning
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Periprosthetic Osteolysis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumothorax Traumatic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Periprosthetic Fracture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Nerve Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Laminectomy Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Procedural Haematoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Procedural Haemorrhage
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Post Procedural Haematuria
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postmastectomy Lymphoedema Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Gastric Surgery Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postoperative Ileus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Procedural Pain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postpericardiotomy Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Procedural Hypotension
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postoperative Thoracic Procedure Complication
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Procedural Intestinal Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pubis Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rib Fracture
|
|
|
|
subjects affected / exposed
|
18 / 9067 (0.20%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 18 |
0 / 16 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Radius Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Radiation Proctitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Contusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Road Traffic Accident
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
Scapula Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Scar
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Scrotal Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Seroma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Shunt Malfunction
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skeletal Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Silicosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Compression Fracture
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skull Fracture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Snake Bite
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Cord Injury Cauda Equina
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Column Injury
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Soft Tissue Injury
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Splenic Rupture
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sternal Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subcutaneous Haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Stoma Site Ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sternal Injury
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subdural Haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Suture Related Complication
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Synovial Rupture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tendon Injury
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tendon Rupture
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
1 / 7 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thermal Burn
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thoracic Vertebral Fracture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Traumatic Fracture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tibia Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Toxicity To Various Agents
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheostomy Malfunction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Transfusion Reaction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Traumatic Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular Graft Occlusion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Upper Limb Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ulna Fracture
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Traumatic Haemothorax
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular Pseudoaneurysm
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Retention Postoperative
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Bladder Rupture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Dehiscence
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Haematoma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Wound
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular Pseudoaneurysm Ruptured
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wrist Fracture
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Congenital, familial and genetic disorders
|
|
|
|
Arteriovenous Malformation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrial Septal Defect
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bicuspid Aortic Valve
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Congenital Spinal Cord Anomaly
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dermoid Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adenomatous Polyposis Coli
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Foramen Magnum Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Arteriovenous Malformation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hydrocele
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertrophic Cardiomyopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Multiple Lentigines Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epidermal Naevus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ventricular Septal Defect
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sickle Cell Anaemia With Crisis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Phimosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac disorders
|
|
|
|
Adams-Stokes Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Angina Pectoris
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Valve Incompetence
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Aortic Valve Stenosis
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Arrhythmia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrioventricular Block
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrial Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrial Flutter
|
|
|
|
subjects affected / exposed
|
24 / 9067 (0.26%) |
28 / 9077 (0.31%) |
|
occurrences causally related to treatment / all
|
0 / 24 |
0 / 28 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrial Fibrillation
|
|
|
|
subjects affected / exposed
|
140 / 9067 (1.54%) |
150 / 9077 (1.65%) |
|
occurrences causally related to treatment / all
|
0 / 140 |
0 / 150 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Arrhythmia Supraventricular
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrial Tachycardia
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bradycardia
|
|
|
|
subjects affected / exposed
|
27 / 9067 (0.30%) |
30 / 9077 (0.33%) |
|
occurrences causally related to treatment / all
|
0 / 27 |
0 / 30 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bradyarrhythmia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrioventricular Dissociation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrioventricular Block Second Degree
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrioventricular Block First Degree
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Atrioventricular Block Complete
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 13 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bundle Branch Block Left
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Arrest
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Failure
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Pseudoaneurysm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bundle Branch Block
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiorenal Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiomyopathy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiogenic Shock
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Cardio-Respiratory Arrest
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Cardiac Ventricular Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiac Tamponade
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Coronary Artery Dissection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cor Pulmonale
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Congestive Cardiomyopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Conduction Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronotropic Incompetence
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cardiovascular Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Coronary Artery Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Coronary Artery Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertensive Cardiomyopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heart Valve Incompetence
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extrasystoles
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dressler's Syndrome
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mitral Valve Incompetence
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Left Ventricular Dysfunction
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myocardial Ischaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ischaemic Cardiomyopathy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intracardiac Thrombus
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mitral Valve Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pericarditis Constrictive
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pericarditis
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pericardial Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Pericardial Effusion
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Palpitations
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Supraventricular Extrasystoles
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myocarditis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sinus Tachycardia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sinus Arrhythmia
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sinus Arrest
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sick Sinus Syndrome
|
|
|
|
subjects affected / exposed
|
17 / 9067 (0.19%) |
19 / 9077 (0.21%) |
|
occurrences causally related to treatment / all
|
0 / 17 |
0 / 19 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Supraventricular Tachycardia
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 18 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Sinus Bradycardia
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Torsade De Pointes
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tachycardia Paroxysmal
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tachycardia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Supraventricular Tachyarrhythmia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ventricular Extrasystoles
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ventricular Fibrillation
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Wolff-Parkinson-White Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ventricular Tachycardia
|
|
|
|
subjects affected / exposed
|
29 / 9067 (0.32%) |
42 / 9077 (0.46%) |
|
occurrences causally related to treatment / all
|
0 / 29 |
0 / 42 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Trifascicular Block
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ventricular Arrhythmia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Nervous system disorders
|
|
|
|
Amyotrophic Lateral Sclerosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Amnesia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carotid Artery Occlusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carotid Artery Aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Brain Injury
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Balance Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Autonomic Nervous System Imbalance
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ataxia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arachnoid Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carotid Sinus Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carpal Tunnel Syndrome
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Central Nervous System Lesion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cerebrospinal Fluid Leakage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Cord Compression
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cerebrovascular Accident
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Carotid Artery Stenosis
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Myelopathy
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Radiculopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cognitive Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Complex Partial Seizures
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Complicated Migraine
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Convulsion
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Cervicobrachial Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Demyelination
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Coma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Hyperglycaemic Coma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Neuropathy
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dizziness
|
|
|
|
subjects affected / exposed
|
30 / 9067 (0.33%) |
30 / 9077 (0.33%) |
|
occurrences causally related to treatment / all
|
0 / 30 |
1 / 30 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dementia Alzheimer's Type
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dementia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Guillain-Barre Syndrome
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Grand Mal Convulsion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Facial Paresis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extrapyramidal Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epilepsy
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Encephalopathy
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypotonia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertensive Encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypoaesthesia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hydrocephalus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatic Encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Hemiparesis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Headache
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
1 / 11 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intercostal Neuralgia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intracranial Aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lethargy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leukoencephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Loss Of Consciousness
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypoxic-Ischaemic Encephalopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Migraine
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Migraine With Aura
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metabolic Encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Lumbar Radiculopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Multiple Sclerosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Motor Neurone Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neurological Symptom
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuralgia
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscle Spasticity
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nervous System Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myasthenia Gravis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myelopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nerve Compression
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Paraplegia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Paraparesis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Paraesthesia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Occipital Neuralgia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Normal Pressure Hydrocephalus
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuropathy Peripheral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Paralysis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Parkinsonism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Partial Seizures
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Perineurial Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peripheral Paralysis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumocephalus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Polyneuropathy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Parkinson's Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Radicular Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Radiculopathy
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sciatica
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Radial Nerve Palsy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polyneuropathy Chronic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Post Polio Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Presyncope
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
20 / 9077 (0.22%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 20 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tarsal Tunnel Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Syncope
|
|
|
|
subjects affected / exposed
|
107 / 9067 (1.18%) |
96 / 9077 (1.06%) |
|
occurrences causally related to treatment / all
|
0 / 107 |
0 / 96 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Somnolence
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Status Epilepticus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spondylitic Myelopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Cord Ischaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Cord Compression
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vascular Dementia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Unresponsive To Stimuli
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tremor
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Transient Global Amnesia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Toxic Encephalopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tension Headache
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Trigeminal Neuralgia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertebrobasilar Insufficiency
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Viith Nerve Paralysis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vith Nerve Paralysis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vith Nerve Paresis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertebral Artery Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blood and lymphatic system disorders
|
|
|
|
Agranulocytosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia Of Chronic Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia Of Malignant Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia Megaloblastic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia
|
|
|
|
subjects affected / exposed
|
71 / 9067 (0.78%) |
55 / 9077 (0.61%) |
|
occurrences causally related to treatment / all
|
1 / 71 |
1 / 55 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anaemia Macrocytic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhagic Diathesis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhagic Anaemia
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemolytic Anaemia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Disseminated Intravascular Coagulation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Coagulopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Febrile Neutropenia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypercoagulation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hilar Lymphadenopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Heparin-Induced Thrombocytopenia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypereosinophilic Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Immune Thrombocytopenic Purpura
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Iron Deficiency Anaemia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Leukocytosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Leukopenia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypochromic Anaemia
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Normochromic Normocytic Anaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Microcytic Anaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphoid Tissue Hyperplasia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphadenopathy Mediastinal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphadenopathy
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymphadenitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thrombocytopenia
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
1 / 6 |
1 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Systemic Mastocytosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Splenic Vein Thrombosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Splenic Lesion
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retroperitoneal Lymphadenopathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancytopenia
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Thrombocytopenic Purpura
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ear and labyrinth disorders
|
|
|
|
Deafness Neurosensory
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Deafness Unilateral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Deafness
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sudden Hearing Loss
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tinnitus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Otorrhoea
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Middle Ear Effusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inner Ear Inflammation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inner Ear Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertigo Positional
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertigo
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
25 / 9077 (0.28%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 25 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eye disorders
|
|
|
|
Blepharitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blindness Transient
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cataract
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 17 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cataract Nuclear
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Corneal Scar
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blindness
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Retinopathy
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eye Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Exfoliation Glaucoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diplopia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eye Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Glaucoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lens Dislocation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Macular Degeneration
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Macular Oedema
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyphaema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retinal Detachment
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Optic Ischaemic Neuropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retinal Artery Occlusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Visual Impairment
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Papilloedema
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vitreous Haemorrhage
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vitreous Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal disorders
|
|
|
|
Abdominal Distension
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Discomfort
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Adhesions
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Mass
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Pain
|
|
|
|
subjects affected / exposed
|
41 / 9067 (0.45%) |
43 / 9077 (0.47%) |
|
occurrences causally related to treatment / all
|
3 / 41 |
1 / 43 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Abdominal Pain Lower
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Hernia
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Pain Upper
|
|
|
|
subjects affected / exposed
|
21 / 9067 (0.23%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
1 / 21 |
1 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Polyp
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Fistula
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Fissure
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Wall Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Wall Haematoma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Barrett's Oesophagus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Ascites
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Prolapse
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bezoar
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Constipation
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
15 / 9077 (0.17%) |
|
occurrences causally related to treatment / all
|
1 / 14 |
1 / 15 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colitis Ischaemic
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colitis Ulcerative
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colitis
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Coeliac Disease
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bowel Movement Irregularity
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diarrhoea
|
|
|
|
subjects affected / exposed
|
23 / 9067 (0.25%) |
15 / 9077 (0.17%) |
|
occurrences causally related to treatment / all
|
1 / 23 |
0 / 15 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Gastroparesis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diaphragmatic Hernia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dental Caries
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cyclic Vomiting Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Crohn's Disease
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulum Intestinal
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulum
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulitis Intestinal Haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticular Perforation
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diarrhoea Haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulum Oesophageal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenal Polyp
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenal Ulcer
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenal Ulcer Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenal Ulcer Haemorrhage
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulum Intestinal Haemorrhagic
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Enterocele
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Enteritis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenitis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dysphagia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
1 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Duodenogastric Reflux
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dyspepsia
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
1 / 11 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Erosive Oesophagitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Enterovesical Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Erosive Duodenitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Enterocolitis Haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Enterocolitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epigastric Discomfort
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Faecaloma
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Femoral Hernia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Food Poisoning
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Haemorrhage
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Faecal Incontinence
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Polyps
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Ulcer
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
1 / 18 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Ulcer Haemorrhage
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastric Ulcer Perforation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastritis
|
|
|
|
subjects affected / exposed
|
29 / 9067 (0.32%) |
39 / 9077 (0.43%) |
|
occurrences causally related to treatment / all
|
1 / 29 |
2 / 39 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Disorder
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Angiodysplasia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroduodenal Ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastritis Haemorrhagic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastritis Erosive
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroduodenitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Pain
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Oedema
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Obstruction
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Necrosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Hypomotility
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
60 / 9067 (0.66%) |
64 / 9077 (0.71%) |
|
occurrences causally related to treatment / all
|
0 / 60 |
0 / 64 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
Gastrointestinal Ulcer Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrooesophageal Reflux Disease
|
|
|
|
subjects affected / exposed
|
27 / 9067 (0.30%) |
33 / 9077 (0.36%) |
|
occurrences causally related to treatment / all
|
0 / 27 |
2 / 33 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gingival Bleeding
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haematemesis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haematochezia
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Perforation
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertrophic Anal Papilla
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hiatus Hernia
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hernial Eventration
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhoids Thrombosed
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhoids
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemorrhoidal Haemorrhage
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inguinal Hernia
|
|
|
|
subjects affected / exposed
|
69 / 9067 (0.76%) |
51 / 9077 (0.56%) |
|
occurrences causally related to treatment / all
|
0 / 69 |
0 / 51 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inflammatory Bowel Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Impaired Gastric Emptying
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ileus Paralytic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Ileus
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ileal Ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inguinal Hernia, Obstructive
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Infarction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Haematoma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Dilatation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Ischaemia
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Intestinal Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Obstruction
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Intestinal Perforation
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Polyp
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Intestine Polyp
|
|
|
|
subjects affected / exposed
|
40 / 9067 (0.44%) |
58 / 9077 (0.64%) |
|
occurrences causally related to treatment / all
|
2 / 40 |
1 / 58 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Intestine Perforation
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Large Intestinal Ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Intestinal Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Large Intestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Irritable Bowel Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intestinal Stenosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mesenteric Artery Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mesenteric Artery Embolism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Melaena
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
1 / 10 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mallory-Weiss Syndrome
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Gastrointestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Lumbar Hernia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mouth Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mouth Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nausea
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
2 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oedematous Pancreatitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Achalasia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mesenteritis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Spasm
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Motility Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Perforation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Rupture
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophagitis
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oral Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatitis Necrotising
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatitis Chronic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatitis Acute
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
3 / 13 |
1 / 17 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatitis
|
|
|
|
subjects affected / exposed
|
35 / 9067 (0.39%) |
28 / 9077 (0.31%) |
|
occurrences causally related to treatment / all
|
10 / 35 |
6 / 28 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Pancreatic Pseudocyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatic Mass
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Pharyngo-Oesophageal Diverticulum
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peptic Ulcer
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Parotid Gland Enlargement
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreatitis Relapsing
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Peritoneal Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Polyp
|
|
|
|
subjects affected / exposed
|
17 / 9067 (0.19%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 17 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Perforation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Haemorrhage
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 17 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Proctalgia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumoperitoneum
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumatosis Intestinalis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Ulcer Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectourethral Fistula
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Reflux Gastritis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retroperitoneal Haematoma
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Retroperitoneal Haemorrhage
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Prolapse
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tongue Dysplasia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subileus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Splenic Artery Aneurysm
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Small Intestinal Obstruction
|
|
|
|
subjects affected / exposed
|
13 / 9067 (0.14%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 13 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Small Intestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Salivary Gland Calculus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vomiting
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
1 / 8 |
2 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Volvulus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Upper Gastrointestinal Haemorrhage
|
|
|
|
subjects affected / exposed
|
26 / 9067 (0.29%) |
25 / 9077 (0.28%) |
|
occurrences causally related to treatment / all
|
0 / 26 |
1 / 25 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Umbilical Hernia, Obstructive
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Umbilical Hernia
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin and subcutaneous tissue disorders
|
|
|
|
Angioedema
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Actinic Keratosis
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 18 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Foot
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dermatomyositis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dermatitis Allergic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dermatitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dermal Cyst
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Decubitus Ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Campbell De Morgan Spots
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Ulcer
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Eczema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ecchymosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Drug Eruption
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Erythema
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Excessive Granulation Tissue
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperkeratosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Granuloma Skin
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypersensitivity Vasculitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lichen Planus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Night Sweats
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Macule
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Palmoplantar Keratoderma
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lichenoid Keratosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Precancerous Skin Lesion
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pityriasis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pemphigoid
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Punctate Keratosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rash
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
1 / 3 |
5 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rash Generalised
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rash Papular
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rash Pruritic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Lesion
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
1 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Burning Sensation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Ulcer
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Solar Lentigo
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subcutaneous Emphysema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Swelling Face
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Toxic Skin Eruption
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urticaria
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal and urinary disorders
|
|
|
|
Bladder Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Diverticulum
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Azotaemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acute Prerenal Failure
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Tamponade
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Spasm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Prolapse
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Neck Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Obstruction
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Neck Sclerosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bladder Perforation
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cystitis Noninfective
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cystitis Haemorrhagic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Crush Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Calculus Bladder
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Calculus Urethral
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Calculus Ureteric
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Calculus Urinary
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypotonic Urinary Bladder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypertonic Bladder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hydronephrosis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Nephropathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
Glomerulonephritis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dysuria
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haematuria
|
|
|
|
subjects affected / exposed
|
27 / 9067 (0.30%) |
20 / 9077 (0.22%) |
|
occurrences causally related to treatment / all
|
0 / 27 |
0 / 20 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pyelocaliectasis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Obstructive Uropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Urinary Tract Symptoms
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nephrosclerosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nephropathy
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nephrolithiasis
|
|
|
|
subjects affected / exposed
|
31 / 9067 (0.34%) |
35 / 9077 (0.39%) |
|
occurrences causally related to treatment / all
|
1 / 31 |
0 / 35 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nephrotic Syndrome
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Failure
|
|
|
|
subjects affected / exposed
|
38 / 9067 (0.42%) |
29 / 9077 (0.32%) |
|
occurrences causally related to treatment / all
|
1 / 38 |
1 / 29 |
|
deaths causally related to treatment / all
|
0 / 7 |
0 / 3 |
|
Renal Embolism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Artery Stenosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Cyst
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Colic
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Cyst Ruptured
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Infarct
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Impairment
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Failure Acute
|
|
|
|
subjects affected / exposed
|
51 / 9067 (0.56%) |
61 / 9077 (0.67%) |
|
occurrences causally related to treatment / all
|
0 / 51 |
0 / 61 |
|
deaths causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
Renal Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Failure Chronic
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Hypertension
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ureteric Obstruction
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ureteric Dilatation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tubulointerstitial Nephritis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Injury
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Tubular Necrosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Renal Mass
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Stress Urinary Incontinence
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Bladder Haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urge Incontinence
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urethral Stenosis
|
|
|
|
subjects affected / exposed
|
9 / 9067 (0.10%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 9 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ureteric Stenosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urethral Dilatation
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urethral Caruncle
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urethral Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Tract Obstruction
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Tract Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Retention
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
27 / 9077 (0.30%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
0 / 27 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Bladder Polyp
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Incontinence
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endocrine disorders
|
|
|
|
Adrenal Insufficiency
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Adrenal Mass
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Basedow's Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Goitre
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Inappropriate Antidiuretic Hormone Secretion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypothyroidism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pituitary Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperparathyroidism Primary
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperparathyroidism
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperthyroidism
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postpartum Hypopituitarism
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Thyroid Haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Toxic Nodular Goitre
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Musculoskeletal and connective tissue disorders
|
|
|
|
Arthritis
|
|
|
|
subjects affected / exposed
|
32 / 9067 (0.35%) |
23 / 9077 (0.25%) |
|
occurrences causally related to treatment / all
|
0 / 32 |
0 / 23 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthralgia
|
|
|
|
subjects affected / exposed
|
25 / 9067 (0.28%) |
23 / 9077 (0.25%) |
|
occurrences causally related to treatment / all
|
0 / 25 |
3 / 23 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bursitis
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Pain
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bone Lesion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthritis Reactive
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthropathy
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthrofibrosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Back Pain
|
|
|
|
subjects affected / exposed
|
36 / 9067 (0.40%) |
34 / 9077 (0.37%) |
|
occurrences causally related to treatment / all
|
0 / 36 |
0 / 34 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Diastasis Recti Abdominis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Costochondritis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Compartment Syndrome
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cervical Spinal Stenosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chest Wall Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chest Wall Cyst
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chondropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Flank Pain
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fistula
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fibromyalgia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dupuytren's Contracture
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Exostosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epiphysitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extraskeletal Ossification
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Groin Pain
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gouty Arthritis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Foot Deformity
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fracture Malunion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fracture Nonunion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Effusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Disc Protrusion
|
|
|
|
subjects affected / exposed
|
28 / 9067 (0.31%) |
35 / 9077 (0.39%) |
|
occurrences causally related to treatment / all
|
0 / 28 |
0 / 35 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Disc Displacement
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemarthrosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Disc Degeneration
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Disc Compression
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metatarsalgia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Disc Disorder
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lumbar Spinal Stenosis
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 18 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Extremity Mass
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Instability
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Knee Deformity
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Limb Discomfort
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Swelling
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Musculoskeletal Discomfort
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Musculoskeletal Chest Pain
|
|
|
|
subjects affected / exposed
|
34 / 9067 (0.37%) |
21 / 9077 (0.23%) |
|
occurrences causally related to treatment / all
|
0 / 34 |
0 / 21 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscular Weakness
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
1 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mobility Decreased
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscle Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Morphoea
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Monarthritis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Muscle Spasms
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
2 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myalgia
|
|
|
|
subjects affected / exposed
|
20 / 9067 (0.22%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
15 / 20 |
10 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Musculoskeletal Pain
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
1 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neck Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myositis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myopathy
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
4 / 6 |
3 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myofascial Pain Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myalgia Intercostal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteonecrosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteolysis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteochondrosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteoarthritis
|
|
|
|
subjects affected / exposed
|
175 / 9067 (1.93%) |
159 / 9077 (1.75%) |
|
occurrences causally related to treatment / all
|
0 / 175 |
0 / 159 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neck Pain
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Neuropathic Arthropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polymyositis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polymyalgia Rheumatica
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
1 / 1 |
1 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Polyarthritis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Periarthritis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pain In Jaw
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pain In Extremity
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
1 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteoporosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rhabdomyolysis
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
10 / 12 |
17 / 18 |
|
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
|
Rheumatic Fever
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rheumatoid Arthritis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
8 / 9077 (0.09%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 8 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rib Deformity
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rotator Cuff Syndrome
|
|
|
|
subjects affected / exposed
|
21 / 9067 (0.23%) |
16 / 9077 (0.18%) |
|
occurrences causally related to treatment / all
|
0 / 21 |
0 / 16 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Scleroderma
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Psoriatic Arthropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Column Stenosis
|
|
|
|
subjects affected / exposed
|
22 / 9067 (0.24%) |
27 / 9077 (0.30%) |
|
occurrences causally related to treatment / all
|
0 / 22 |
0 / 27 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Disorder
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Osteoarthritis
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spinal Pain
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spondylitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Spondylolisthesis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Soft Tissue Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Synovitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Systemic Lupus Erythematosus
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Synovial Disorder
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Synovial Cyst
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tendon Disorder
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tendonitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tenosynovitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vertebral Foraminal Stenosis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Upper Extremity Mass
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Torticollis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infections and infestations
|
|
|
|
Abscess Intestinal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Wall Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Wall Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abdominal Sepsis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Abdominal Abscess
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abscess Neck
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abscess Limb
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abscess Jaw
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Alpha Haemolytic Streptococcal Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Acute Sinusitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abscess Oral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthritis Bacterial
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Anal Abscess
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Appendicitis Perforated
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Appendicitis
|
|
|
|
subjects affected / exposed
|
33 / 9067 (0.36%) |
18 / 9077 (0.20%) |
|
occurrences causally related to treatment / all
|
0 / 33 |
0 / 18 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Arthritis Infective
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Appendiceal Abscess
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Blister Infected
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bacterial Sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bacterial Infection
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bacteraemia
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Biliary Sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Breast Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchiolitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchitis
|
|
|
|
subjects affected / exposed
|
49 / 9067 (0.54%) |
43 / 9077 (0.47%) |
|
occurrences causally related to treatment / all
|
0 / 49 |
0 / 43 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchitis Bacterial
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Brain Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchitis Viral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Campylobacter Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Bronchopneumonia
|
|
|
|
subjects affected / exposed
|
17 / 9067 (0.19%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 17 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
Campylobacter Gastroenteritis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cellulitis
|
|
|
|
subjects affected / exposed
|
49 / 9067 (0.54%) |
63 / 9077 (0.69%) |
|
occurrences causally related to treatment / all
|
0 / 49 |
0 / 63 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
Cardiac Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Chronic Sinusitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholecystitis Infective
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cellulitis Of Male External Genital Organ
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Candida Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cystitis
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Coccidioidomycosis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Colonic Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Clostridium Difficile Sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Clostridium Difficile Colitis
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Clostridium Difficile Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Device Related Infection
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Foot Infection
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diarrhoea Infectious
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Gangrene
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diverticulitis
|
|
|
|
subjects affected / exposed
|
34 / 9067 (0.37%) |
37 / 9077 (0.41%) |
|
occurrences causally related to treatment / all
|
0 / 34 |
0 / 37 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Dengue Fever
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Echinococciasis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Ear Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Empyema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Encephalitis Viral
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endocarditis Bacterial
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endocarditis Enterococcal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Encephalitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endocarditis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Emphysematous Cholecystitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Escherichia Bacteraemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Erysipelas
|
|
|
|
subjects affected / exposed
|
18 / 9067 (0.20%) |
14 / 9077 (0.15%) |
|
occurrences causally related to treatment / all
|
0 / 18 |
0 / 14 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epididymitis
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epidemic Nephropathy
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Endophthalmitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Epiglottitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Extradural Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Folliculitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Febrile Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gangrene
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gallbladder Empyema
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis
|
|
|
|
subjects affected / exposed
|
51 / 9067 (0.56%) |
44 / 9077 (0.48%) |
|
occurrences causally related to treatment / all
|
0 / 51 |
0 / 44 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Fungal Skin Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fungal Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Furuncle
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis Bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis Rotavirus
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis Salmonella
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastroenteritis Viral
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Candidiasis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gastrointestinal Infection
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Gastroenteritis Norovirus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hand-Foot-And-Mouth Disease
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
H1n1 Influenza
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gingival Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Groin Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Groin Abscess
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Helicobacter Gastritis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Graft Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Implant Site Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hiv Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Herpes Simplex Encephalitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatitis C
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hepatitis B
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Herpes Zoster
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incision Site Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infected Bites
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incisional Hernia Gangrenous
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infected Cyst
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infected Dermal Cyst
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infected Skin Ulcer
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Incision Site Cellulitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Influenza
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
6 / 9077 (0.07%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Intervertebral Discitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infection
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Infectious Pleural Effusion
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infectious Colitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Infective Exacerbation Of Chronic Obstructive Airways Disease
|
|
|
|
subjects affected / exposed
|
7 / 9067 (0.08%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Joint Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Kidney Infection
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lobar Pneumonia
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Liver Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Laryngitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Labyrinthitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Klebsiella Sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lyme Disease
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Localised Infection
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Respiratory Tract Infection Viral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lower Respiratory Tract Infection
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
1 / 10 |
1 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lung Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Meningitis Viral
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Meningitis Aseptic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Lymph Node Tuberculosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mediastinitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Mastoiditis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Meningitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Orchitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Oesophageal Candidiasis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myelitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Nasopharyngitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Myringitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Necrotising Fasciitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Perineal Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Parotitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pancreas Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteomyelitis
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
10 / 9077 (0.11%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 10 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Otitis Media
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Osteomyelitis Chronic
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Otitis Media Chronic
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Periumbilical Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peritonsillar Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Periodontitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peritonitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
Perirectal Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Peritonitis Bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Influenzal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Chlamydial
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Bacterial
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Pharyngitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumococcal Sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pilonidal Cyst
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia
|
|
|
|
subjects affected / exposed
|
255 / 9067 (2.81%) |
242 / 9077 (2.67%) |
|
occurrences causally related to treatment / all
|
0 / 255 |
1 / 242 |
|
deaths causally related to treatment / all
|
0 / 17 |
0 / 12 |
|
Post Procedural Infection
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Viral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Legionella
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Pseudomonal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Pneumococcal
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pneumonia Streptococcal
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pseudomonas Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pseudomembranous Colitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postoperative Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Proctitis Infectious
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Postoperative Wound Infection
|
|
|
|
subjects affected / exposed
|
8 / 9067 (0.09%) |
13 / 9077 (0.14%) |
|
occurrences causally related to treatment / all
|
0 / 8 |
0 / 13 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Prostate Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Q Fever
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pyomyositis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pyelonephritis Acute
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Psoas Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Pulmonary Tuberculosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Pulmonary Sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Pyelonephritis
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Respiratory Tract Infection
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Renal Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rectal Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Respiratory Tract Infection Viral
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rotavirus Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Rhinitis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Scrotal Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Shunt Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Serratia Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sepsis
|
|
|
|
subjects affected / exposed
|
37 / 9067 (0.41%) |
33 / 9077 (0.36%) |
|
occurrences causally related to treatment / all
|
0 / 37 |
0 / 33 |
|
deaths causally related to treatment / all
|
0 / 7 |
0 / 8 |
|
Septic Encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sepsis Syndrome
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Septic Shock
|
|
|
|
subjects affected / exposed
|
12 / 9067 (0.13%) |
12 / 9077 (0.13%) |
|
occurrences causally related to treatment / all
|
0 / 12 |
0 / 12 |
|
deaths causally related to treatment / all
|
0 / 6 |
0 / 6 |
|
Staphylococcal Infection
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Staphylococcal Bacteraemia
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sinusitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Soft Tissue Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Skin Infection
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Staphylococcal Abscess
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tick-Borne Fever
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sweat Gland Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subcutaneous Abscess
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Staphylococcal Sepsis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Streptococcal Infection
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Sternitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Subacute Endocarditis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Upper Respiratory Tract Infection
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheitis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tooth Abscess
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tonsillitis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tracheobronchitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urinary Tract Infection
|
|
|
|
subjects affected / exposed
|
77 / 9067 (0.85%) |
79 / 9077 (0.87%) |
|
occurrences causally related to treatment / all
|
0 / 77 |
0 / 79 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Tuberculosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Abscess
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Viral Upper Respiratory Tract Infection
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Vestibular Neuronitis
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Urosepsis
|
|
|
|
subjects affected / exposed
|
19 / 9067 (0.21%) |
19 / 9077 (0.21%) |
|
occurrences causally related to treatment / all
|
0 / 19 |
0 / 19 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
Urinary Tract Infection Bacterial
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Viral Infection
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Sepsis
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Wound Infection
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
4 / 9077 (0.04%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Metabolism and nutrition disorders
|
|
|
|
Dehydration
|
|
|
|
subjects affected / exposed
|
34 / 9067 (0.37%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 34 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Abnormal Loss Of Weight
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cholesterosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Cachexia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Decreased Appetite
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Fluid Overload
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Failure To Thrive
|
|
|
|
subjects affected / exposed
|
3 / 9067 (0.03%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Diabetic Ketoacidosis
|
|
|
|
subjects affected / exposed
|
2 / 9067 (0.02%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetes Mellitus
|
|
|
|
subjects affected / exposed
|
22 / 9067 (0.24%) |
29 / 9077 (0.32%) |
|
occurrences causally related to treatment / all
|
0 / 22 |
0 / 29 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetes With Hyperosmolarity
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetes Mellitus Inadequate Control
|
|
|
|
subjects affected / exposed
|
14 / 9067 (0.15%) |
22 / 9077 (0.24%) |
|
occurrences causally related to treatment / all
|
0 / 14 |
0 / 22 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Diabetic Complication
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
Hyperglycaemia
|
|
|
|
subjects affected / exposed
|
15 / 9067 (0.17%) |
11 / 9077 (0.12%) |
|
occurrences causally related to treatment / all
|
0 / 15 |
0 / 11 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperkalaemia
|
|
|
|
subjects affected / exposed
|
16 / 9067 (0.18%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 16 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypercalcaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Glucose Tolerance Impaired
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Haemochromatosis
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Gout
|
|
|
|
subjects affected / exposed
|
4 / 9067 (0.04%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 4 |
1 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperammonaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Malnutrition
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypovolaemia
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
2 / 9077 (0.02%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyponatraemia
|
|
|
|
subjects affected / exposed
|
10 / 9067 (0.11%) |
9 / 9077 (0.10%) |
|
occurrences causally related to treatment / all
|
0 / 10 |
0 / 9 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hyperosmolar State
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypoglycaemia
|
|
|
|
subjects affected / exposed
|
20 / 9067 (0.22%) |
17 / 9077 (0.19%) |
|
occurrences causally related to treatment / all
|
0 / 20 |
0 / 17 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypocalcaemia
|
|
|
|
subjects affected / exposed
|
0 / 9067 (0.00%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Hypokalaemia
|
|
|
|
subjects affected / exposed
|
6 / 9067 (0.07%) |
3 / 9077 (0.03%) |
|
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Type 2 Diabetes Mellitus
|
|
|
|
subjects affected / exposed
|
11 / 9067 (0.12%) |
5 / 9077 (0.06%) |
|
occurrences causally related to treatment / all
|
0 / 11 |
0 / 5 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Obesity
|
|
|
|
subjects affected / exposed
|
5 / 9067 (0.06%) |
7 / 9077 (0.08%) |
|
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Tumour Lysis Syndrome
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
Overweight
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
0 / 9077 (0.00%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
|
Type 1 Diabetes Mellitus
|
|
|
|
subjects affected / exposed
|
1 / 9067 (0.01%) |
1 / 9077 (0.01%) |
|
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
|
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |